View Author
fviii patient willebrand ddavp von willebrand disease erasmus univ rotterdam type 2 fviii /vwf vwf multimers disease response vwf parameters type 1 factor type 2 vwd multimer treatment level study value parameter table loading dose prophylaxi hemate-p rotterdam recessive von willebrand factor half life times erasmu alphanate ratio downloaded cat.sagepub.com type 3 vwd vwd patients absence immunate 12 hours michiel vwf multimeric pattern loading multimeric thromb surgery bleeding minute triplet structure haemate-p blood effect type 2 m platelet pattern recessive type 1 mutation recovery laboratory group ivy bt defect correction facteur willebrand type 1 vwd alphanate sd infusion alphanate sd /ht deficiency plasma structure pharmacokinetic presence weight post-infusion haemosta vwf deficiency vivo recoveries hemostatic effect mannucci factor 8 y
1 Most Recent Publications
|
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease type 1, 2 and 3
(Article)
Michiels, J.J. Vliet, H.H.D.M. van Berneman, Z. Gadisseur, A. Planken, M. van der Schroyens, W. Velden, A. van der Budde, U. |
2007-01-01
|